BidaskClub Lowers Aclaris Therapeutics (ACRS) to Strong Sell

Aclaris Therapeutics (NASDAQ:ACRS) was downgraded by BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Thursday.

A number of other brokerages also recently weighed in on ACRS. Cantor Fitzgerald reissued a “buy” rating on shares of Aclaris Therapeutics in a report on Tuesday, July 17th. Zacks Investment Research raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 24th. Finally, JMP Securities cut their price target on shares of Aclaris Therapeutics from $47.00 to $34.00 and set a “buy” rating on the stock in a report on Tuesday, October 16th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $40.40.

ACRS opened at $10.62 on Thursday. The firm has a market cap of $372.39 million, a price-to-earnings ratio of -4.25 and a beta of 1.50. Aclaris Therapeutics has a 1 year low of $10.52 and a 1 year high of $26.25.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.25) by $0.19. The company had revenue of $1.63 million for the quarter, compared to the consensus estimate of $1.58 million. Aclaris Therapeutics had a negative net margin of 1,578.24% and a negative return on equity of 63.74%. As a group, sell-side analysts anticipate that Aclaris Therapeutics will post -4.27 earnings per share for the current fiscal year.

In other news, Director Stephen A. Tullman acquired 6,250 shares of the stock in a transaction that occurred on Wednesday, August 15th. The shares were acquired at an average cost of $15.97 per share, for a total transaction of $99,812.50. Following the purchase, the director now owns 163,757 shares of the company’s stock, valued at approximately $2,615,199.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Anand Mehra acquired 372,093 shares of the stock in a transaction that occurred on Monday, October 22nd. The stock was purchased at an average price of $10.75 per share, for a total transaction of $3,999,999.75. The disclosure for this purchase can be found here. Insiders purchased a total of 392,043 shares of company stock worth $4,298,212 over the last 90 days. 17.00% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in the stock. MetLife Investment Advisors LLC raised its stake in Aclaris Therapeutics by 32.7% in the 2nd quarter. MetLife Investment Advisors LLC now owns 13,157 shares of the biotechnology company’s stock valued at $263,000 after acquiring an additional 3,244 shares during the period. Russell Investments Group Ltd. raised its stake in Aclaris Therapeutics by 7.4% in the 1st quarter. Russell Investments Group Ltd. now owns 49,450 shares of the biotechnology company’s stock valued at $867,000 after acquiring an additional 3,421 shares during the period. Alps Advisors Inc. raised its stake in Aclaris Therapeutics by 8.4% in the 2nd quarter. Alps Advisors Inc. now owns 44,847 shares of the biotechnology company’s stock valued at $896,000 after acquiring an additional 3,478 shares during the period. Metropolitan Life Insurance Co. NY raised its stake in Aclaris Therapeutics by 48.1% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 11,056 shares of the biotechnology company’s stock valued at $221,000 after acquiring an additional 3,589 shares during the period. Finally, Cadence Capital Management LLC raised its stake in Aclaris Therapeutics by 12.1% in the 2nd quarter. Cadence Capital Management LLC now owns 33,286 shares of the biotechnology company’s stock valued at $665,000 after acquiring an additional 3,593 shares during the period. Institutional investors and hedge funds own 99.83% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Read More: How a Put Option Works

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply